Germany Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.
Germany bladder cancer market is estimated to grow considerably, at a CAGR of around 9.9% during the forecast period. Germany has a considerable market share in the global bladder cancer market due to the increasing geriatric population, presence of highly specialized urologists for cancer treatment and a bit lower cost treatment as compared to the UK, attracting medical tourism in the country. All these factors are contributing to the growth of the market. Germany has a well-developed healthcare system and favorable government policies which are driving the market in the region.
According to the World Health Organization (WHO), in 2018, the bladder cancer accounted for 5.9% of the overall new cases registered in Germany. Moreover, a total of 608,742 new cases of cancer were registered in 2018, among which, around 35,738 cases were registered for bladder cancer in the country. In the case of males, the incidence of bladder cancer registered higher as compared to the country average. It registered around 8.4% of the overall cases registered for men. Furthermore, the total number of deaths caused due to bladder cancer was nearly 8,874 in 2018 in Germany. These figures signify a significant potential for the growth of the market in Germany.
Germany bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most commonly used method in the diagnosis and treatment of bladder cancer. The cystoscopy uses special tools that may be passed through cystoscope to treat very small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.
The companies which are contributing to the growth of the Germany bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the Germany bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation:
1. Germany Bladder Cancer Market Research and Analysis by Cancer Type
2. Germany Bladder Cancer Market Research and Analysis by Diagnosis
3. Germany Bladder Cancer Market Research and Analysis by Treatment
The Report Covers:
Germany bladder cancer market is estimated to grow considerably, at a CAGR of around 9.9% during the forecast period. Germany has a considerable market share in the global bladder cancer market due to the increasing geriatric population, presence of highly specialized urologists for cancer treatment and a bit lower cost treatment as compared to the UK, attracting medical tourism in the country. All these factors are contributing to the growth of the market. Germany has a well-developed healthcare system and favorable government policies which are driving the market in the region.
According to the World Health Organization (WHO), in 2018, the bladder cancer accounted for 5.9% of the overall new cases registered in Germany. Moreover, a total of 608,742 new cases of cancer were registered in 2018, among which, around 35,738 cases were registered for bladder cancer in the country. In the case of males, the incidence of bladder cancer registered higher as compared to the country average. It registered around 8.4% of the overall cases registered for men. Furthermore, the total number of deaths caused due to bladder cancer was nearly 8,874 in 2018 in Germany. These figures signify a significant potential for the growth of the market in Germany.
Germany bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most commonly used method in the diagnosis and treatment of bladder cancer. The cystoscopy uses special tools that may be passed through cystoscope to treat very small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.
The companies which are contributing to the growth of the Germany bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the Germany bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- White papers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation:
1. Germany Bladder Cancer Market Research and Analysis by Cancer Type
2. Germany Bladder Cancer Market Research and Analysis by Diagnosis
3. Germany Bladder Cancer Market Research and Analysis by Treatment
The Report Covers:
- Comprehensive research methodology of the Germany bladder cancer market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Germany bladder cancer market.
- Insights about market determinants which are stimulating the Germany bladder cancer market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bavarian Nordic A/S
- Bayer AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Merck KGaA
- Pfizer Inc.
- Photocure ASA
- Sanofi SA
- Sysmex Corp.